RT Journal Article
T1 Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report.
A1 Jurado, José Miguel
A1 Zarcos, Irene
A1 Delgado, Mayte
A1 Blancas, Isabel
A1 Legerén, Marta
A1 García-Puche, José Luis
K1 Temsirolimus
K1 mThor inhibitors
K1 Metastatic renal
K1 Carcinoma
K1 Matástasis
K1 Carcinoma renal
K1 Inhibidores de la angiogénesis
K1 Tomografía computarizada por rayos X
K1 Relación dosis-respuesta a droga
K1 Hipercolesterolemia
K1 Hipertrigliceridemia
K1 Hipotiroidismo
K1 Neoplasias renales
K1 Leucopenia
K1 Masculinos
K1 Adulto
K1 Anemia
K1 Antiinflamatorios
K1 Fiebre
AB During the last decade, we have been developing new therapeutic strategies for the treatment of renal cancer, based on knowledge derived from molecular biology. We report a case of long-term renal metastatic cancer progression despite therapy with sunitinib and interleukin, which are the most active drugs in renal cancer. Disease stabilization for 58 weeks was achieved upon sequential use of temsirolimus, following the occurrence of disease progression during angiogenic therapy. The patient demonstrated excellent tolerance without marked symptoms for 10 months. Hypothyroidism and mumps-related adverse events were present. The survival time from diagnosis to lung metastasis was 8 years. Thus, this case demonstrates promising therapeutic effects of the sequential use of tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors during different stages of the disease.
PB Spandidos Publications
SN 1792-1074
YR 2013
FD 2013-04
LK http://hdl.handle.net/10668/1885
UL http://hdl.handle.net/10668/1885
LA en
NO Jurado JM, Zarcos I, Delgado M, Blancas I, Legerén M, García-Puche JL. Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report. Oncol Lett. 2013 Apr; 5(4):1382-1384
NO JOURNAL ARTICLE
DS RISalud
RD Apr 9, 2025